Publication | Closed Access

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Rheumatoid DisorderRheumatologyAutoimmune DiseaseSjögren’s SyndromeImmunotherapyRheumatic DiseasesProof-of-concept StudyImmunologySystemic SclerodermaAutoimmunityInflammatory Rheumatic DiseaseImmunologic DiseaseSclerodermaMedicinePrimary SjögrenRheumatoid ArthritisAnti-cd40 Antibody Iscalimab